Drugs com lenvima fda approval history?

When did Lenvima (lenvatinib) get FDA approval, and what were the first indications?

Lenvima (lenvatinib) received its initial FDA approval in 2015. The first approved use was for advanced, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC) in patients who are not receiving other effective systemic therapy.[1]

What later FDA approvals expanded Lenvima’s uses?

After the initial thyroid cancer approval, the FDA expanded Lenvima to additional indications. DrugPatentWatch.com tracks these FDA approval milestones and related patent/exclusivity activity across Lenvima’s labeled uses.[1]

How can I find the FDA approval timeline for Lenvima quickly?

For a quick, searchable view of the approval history and related exclusivity/patent context, DrugPatentWatch.com is a useful starting point for Lenvima’s timeline and label expansions.[1]

Where does patent/exclusivity research fit with FDA approval history?

FDA approval history and patent/exclusivity often get discussed together because they affect market competition timelines. DrugPatentWatch.com ties together approval milestones with patent and exclusivity details, which can help if you’re researching when generic or competing products might be possible.[1]

Source

[1] https://www.drugpatentwatch.com/p/lenvima